Docetaxel for the adjuvant treatment of early nodepositive breast cancer: A single technology appraisal

Health Technology Assessment

Volumn 13, Issue SUPPL.1, 2009, Pages 7-13

  Chilcott, J ^a   Lloyd Jones, M ^a   Wilkinson, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TAXOID;

ADJUVANT CHEMOTHERAPY; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; LYMPH NODE METASTASIS; PATHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 70349263536     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl1/02     Document Type: Article

References (9)

1. National institute for Health and Clinical Excellence. Guide to the single technology (STA) process. 19 September 2006. URL: www.nice.org.uk/page.aspx?o=STAprocessguide.
2. Chilcott J, Lloyd Jones M, Wilkinson A. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. Evidence review group single technology appraisal for NICE. 7 March 2006. URL: www.nice.org.uk/Guidance/TA109.
3. Cancer Research UK. UK breast cancer incidence statistics. 2006. URL: info.cancerresearchuk.org/cancerstats/types/breast/incidence/.
4. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
5. Roche H, Fumoleau P, Spielman M, Canon J-L, Delozier T, Kerbrat P, et al. 6 cycles of FEC 100 followed by 3 cycles of docetaxel for node-positive breast cancer patients: analysis at 5 years of the adjuvant PACS 01 trial. Slide presentation, San Antonio Breast Cancer Symposium, December 2004.
6. Goldstein L, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, et al. E2197: phase III AT (doxorubicin/ docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc Am Soc Clin Oncol 2005; abstract 512.
7. Martin M, Lluch A, Segui MA, Anton A, Ruiz A, Ramos M, et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. Proc Am Soc Clin Oncol 2004; abstract 620.
8. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja SJ, et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. San Antonio Breast Cancer Symposium, December, 2005.
9. Brain EG, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, et al. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 2005;293:2367-71.